Physician profile
Matthew D Stephen
NPI 1861572596
$7,582.37
in general payments reported to CMS, 2019-2025
9 companies · $7,398 in 2025
The $7,398 reported for 2025 was more than what 86% of Pediatric Endocrinology providers received nationally (typical 2025 total: $294).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $30.00 · 2020: $103 · 2022: $7.58 · 2023: $27.73 · 2024: $16.05 · 2025: $7,398.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $6,870 · Food and Beverage: $357 · Travel and Lodging: $192 · Education: $23.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $6,870.00 |
| Food and Beverage | $356.80 |
| Travel and Lodging | $191.80 |
| Education | $23.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $7,207.03 | 2025 | |
| Novo Nordisk INC | $203.92 | 2020-2025 | Wegovy |
| Neurocrine Biosciences, INC. | $60.71 | 2025 | |
| Ultragenyx Pharmaceutical INC. | $30.00 | 2019 | |
| Soleno Therapeutics, INC. | $29.35 | 2025 | Vykat Xr |
| Rhythm Pharmaceuticals, INC. | $27.73 | 2023 | Imcivree |
| Abbott Laboratories | $16.05 | 2024 | Freestyle Libre 3 |
| Ascendis Pharma Endocrinology INC | $7.58 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Stephen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.